1046-57-7

Usage

Uses

Used in Pharmaceutical Research:
3,5,6-TRI(2-PYRIDYL)-1,2,4-TRIAZINE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its structural properties make it a promising candidate for medicinal chemistry, where it can be incorporated into drug molecules to enhance their therapeutic effects.
Used in Coordination Chemistry:
In the field of coordination chemistry, 3,5,6-TRI(2-PYRIDYL)-1,2,4-TRIAZINE is used as a ligand to form complexes with metal ions. This application is crucial for the advancement of catalysis and material science, as these complexes can exhibit unique catalytic properties and contribute to the creation of new materials with specific functionalities.
Used in Catalyst Development:
3,5,6-TRI(2-PYRIDYL)-1,2,4-TRIAZINE is utilized as a component in the development of catalysts due to its ability to chelate metal ions. The resulting metal complexes can improve the efficiency and selectivity of various chemical reactions, making it an important compound in the design of homogeneous and heterogeneous catalysts.
Used in Material Science:
In material science, 3,5,6-TRI(2-PYRIDYL)-1,2,4-TRIAZINE is employed in the synthesis of advanced materials, such as metal-organic frameworks (MOFs) and coordination polymers. These materials can exhibit unique properties, such as high porosity, stability, and responsiveness to external stimuli, making them suitable for applications in gas storage, separation, and sensing.
Overall, 3,5,6-TRI(2-PYRIDYL)-1,2,4-TRIAZINE is a valuable and versatile chemical compound with diverse potential applications across various scientific disciplines, including chemistry, pharmaceuticals, catalysis, and material science. Its unique structural features and ability to form complexes with metal ions make it an essential component in the development of innovative solutions and technologies.

InChI:InChI=1/C18H12N6/c1-4-10-19-13(7-1)16-17(14-8-2-5-11-20-14)23-24-18(22-16)15-9-3-6-12-21-15/h1-12H

Upstream product

• 492-73-9 2,2'-Pyridil 
• 1005-02-3 2-pyridinecarbohydrazonamide 
• 100-70-9 2-Cyanopyridine 
• 1141-06-6 2-hydroxy-1,2-di-2-pyridylethanone 

Relevant academic research and scientific papers

A new and simple 'LEGO' system for the synthesis of branched oligopyridines

The condensation of carboxamidrazones 1 with 1,2-dicarbonyl compounds 2 is the best method for the synthesis of alkyl, aryl or hetaryl substituted 1,2,4-triazines 3 - 7. These 1,2,4-triazines can be easily transformed to pyridines 8 - 12 by [4+2] cycloaddition with bicyclo[2.2.1]hepta-2,5-diene followed by [4+2] cycloreversions of nitrogen and cyclopentadiene. This reaction sequence offers a new, simple and general access to branched oligopyridines.

Palladium(II)complexes of ambidentate and potentially cyclometalating 5-aryl-3-(2′-pyridyl)-1,2,4-triazine ligands

The 5-aryl-3-(2′-pyridiyl)-1,2,4-triazine ligands under study [5-phenyl-(PyTZPh)L1 5-(3-methoxyphenyl)-(PyTZ3Me-OPh)L2 5-(4-methoxyphenyl)-(PyTZ4MeOPh)L3 5-(4-trifluoromethylphenyl)-(PyTZ4CF3Ph)L4 5-(4-fluorophenyl)-(PyTZ4FPh)L5 and tris-3,5,6-(2′-pyridyl)-1,2,4-triazine (Py3TZ)L6] react with [(COD)PdCl2] (COD = 1,5-cyclooctadiento form complexes [(L1-6)PdCl2] with N,N bidentate binding ligands, also including the potentially N,N,N tridentate ligand L6. This was concluded from an in-depth NMR spectroscopic study of the new complexes and from comparison with Pd-terpy complexes [(R′ terpy)PdCl]Cl [R′terpy = 4′-R′-2,2′:6′,2′′-terpyridine R′ = H or SMe], showing definite tridentate N,N,N coordination, and with the Pd-bpy complexes [(bpy)Pd(Mes)Cl] and [(bpy)PdCl2], show-ing definite bidentate N,N binding. The new ligands and complexes were fully characterised by multinuclear NMR spectroscopy, IR spectroscopy and mass spectrometry. No evidence for the parent triazine complexes is observed in EI-MS instead, cyclometalated complexes (HCl eliminatiowere detected in all cases. TDA/TG experiments support this assumption. Attempts to prepare the cyclometalated derivatives as substances failed, in line with the unfavourable binding mode. Detailed electrochemical measurements reveal ligand-centred reductions at very moderate potentials, in line with UV/Vis absorption spectroscopy and DFT calculations, revealing very low-lying triazine-centred LUMOs. Results from cyclic voltammetry also support the composition of [(Py3TZ)PdCl2].